Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch

Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the launch of the company's new ...

Critical Perspective on Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch

//www.cnbc.com/2026/01/16/novo-nordisk-shares-wegovy-obesity-pill-launch.html: Skip NavigationMarketsBusinessInvestingTechPoliticsVideoWatchlistInvesting ClubPROLivestreamMenuKey PointsShares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the launch of the company's new GLP-1 pill for obesity in the U.S.In a Friday note, TD Cowen analysts called it a "solid start" but cautioned that they need to see more data to fully assess early demand for the Wegovy pill.The initial data is a boost to the Danish drugmaker's hopes of winning back more share from its chief rival, Eli Lilly, in the booming market for obesity and diabetes drugs.In this articleNVOFollow your favorite stocksCREATE FREE ACCOUNTA pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan.

For more details, check out College students and teens could be fueling the prediction markets boom.

You might also like: Trump Investors Homes Family Offices.

Related reading: Faisal Islam Global Disruption Looms 000038559.

15, 2026.George Frey | Bloomberg | Getty ImagesShares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company's new GLP-1 pill for obesity.In a Friday note, TD Cowen analysts called it a "solid start" for the first-ever weight loss pill, but said "one data point does not make a trend." They cautioned that they need to see more data to fully assess early demand for the Wegovy pill, which officially launched Jan. Novo Nordisk Shares Novo Nordisk Wegovy Novo Nordisk Shares

5 after winning approval in late December. Still, the initial data is a boost to the Danish drugmaker's hopes of winning back more share from its chief rival, Eli Lilly, this year in the booming obesity and diabetes drug market. Eli Lilly won the majority market share in early 2025 and is trailing closely behind Novo Nordisk in the pill space, as it prepares for the upcoming launch of its own oral drug for obesity.In a Friday note, Leerink Partners analyst David Risinger said around 3,100 prescriptions for the Wegovy pill were filled in the first week of the launch, citing IQVIA data for the week ending Jan.

9. In the first week of the commercial launch of Eli Lilly's popular obesity injection, Zepbound, around 1,300 prescriptions were fi